Hélène Pasquer

Inserm — France

Medicine · Health Sciences

7h-index155citations41works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(23), Nanoparticle-Based Drug Delivery(20), RNA Interference and Gene Delivery(20), Acute Myeloid Leukemia Research(10), Myeloproliferative Neoplasms: Diagnosis and Treatment(9)

Publications41 total

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study
HemaSphere·2025· 1 citedOpen Access
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
Nature Communications·2025· 3 citedOpen Access
AML patient blasts exhibit polarization defects upon interaction with bone marrow stromal cells
EMBO Reports·2025· 1 citedOpen Access
Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study
Blood·2024· 1 cited
JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities
Blood·2024
<i>SH2B3 L</i>oss of Function Variants Are Potential Drivers of Severe Thrombocytosis
Blood·2024· 1 cited
Current myeloproliferative neoplasm scoring systems for clinical practice
Blood·2024· 8 cited
Supplementary Figure S1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S7 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Data from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S5 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Lina Benajiba(38), Alexandre Puissant(28), Loïs Kelly(27), Manuela Bratti(23), Elisa Stubbs(23), Sergii Kolodych(23), Hervé Souchet(23), Johanna Merlin(23), Michelle Marchal(23), Rémy Castellano(23), Emmanuelle Josselin(23), Oleksandr Koniev(23), Yves Collette(23), Coralie Bélanger(23), Olivier Hermine(23), Renato C. Monteiro(23), Pierre Launay(23), Emmanuel Raffoux(10), Jean‐Jacques Kiladjian(9), Bruno Cassinat(7)